Eli Lilly expected to outperform with strong revenue growth and promising new products

From Nasdaq: 2025-03-02 15:39:00

Eli Lilly (NYSE: LLY) has been a top-performing pharmaceutical giant in the past five years, with strong revenue growth and promising new products in its portfolio. Analysts predict peak annual sales of $25 billion for its diabetes and weight management treatments. The company’s revenue is expected to continue growing at a good clip, with pipeline progress showing potential for even more growth. While the stock has a forward P/E ratio of 39, higher than the industry average, it remains fairly valued given its growth and innovation. Eli Lilly is expected to outperform the market in the next five years.

For more news like this, sign up for free Breakfast news in your inbox every market day.

The Motley Fool Stock Advisor team has identified 10 best stocks to buy now, but Eli Lilly wasn’t on the list. Consider joining Stock Advisor for guidance on building a successful portfolio and receiving regular updates and stock picks. The service has significantly outperformed the S&P 500 since 2002.

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk.



Read more at Nasdaq: Where Will Eli Lilly Be in 5 Years?